Local manufacturing for market access

Local manufacturing for market access is the service of establishing biopharmaceutical production inside a target country or region so that a product qualifies for market entry, government procurement preference and supply security, typically through a CDMO, technology transfer or a joint local-build. It is surging because governments are treating domestic drug supply as strategic: Thermo Fisher flags 500 billion US dollars of announced US biomanufacturing investments by big pharma as a structural tailwind and is itself executing a 1 billion US dollar CDMO investment plan. CDMOs with a global footprint convert that demand into capacity, with Lonza citing its available US capacity and global network as a core competitive advantage and WuXi Biologics running roughly 580,000 litres of installed biologic capacity across a network that now extends to Singapore and Qatar. For emerging markets, local manufacturing is also a market-access condition: Biocon Biologics earned EMA approval of a new monoclonal-antibody facility in India alongside GMP renewals for its India and Malaysia sites, turning local build into EU market access.

The key directions of local manufacturing for market access are:

1. Contract development and manufacturing (CDMO services): outsourcing local production to a global CDMO (Catalent, Lonza, Thermo Fisher Patheon) with an existing GMP site in the target market.
2. Technology transfer (Process transfer): transferring a validated process from an originator to a local manufacturer under GMP, including analytical comparability.
3. Modular local build (Modular biomanufacturing): deploying pre-fabricated, modular biologics plants (WuXi Biologics Singapore) to compress time-to-capacity.
4. Multi-site GMP network qualification (Network access): qualifying a network of GMP sites across jurisdictions so one product can be supplied to many markets from different origins.

Sectoral value chain#

[Market-access & site decision] ──> [CDMO selection / local partner] ──> [Technology transfer] ──> [GMP build & qualification]
                                            │
                                  (Regulatory filing)
                                            │
                                            ▼
[Commercial supply] <─── [Inspection & approval] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• CDMO multi-site networks: global GMP capacity (Lonza Visp/US, Catalent, Thermo Fisher Patheon) that lets a sponsor manufacture in-region without owning a plant.
• Modular biomanufacturing: pre-fabricated biologics modules (WuXi Biologics Singapore) that cut construction and commissioning time.
• Technology transfer toolkits: standardised process, analytical and comparability packages that move a product between sites with minimal revalidation.

The local-manufacturing stack is built on multi-site CDMO networks, modular plant design and disciplined technology transfer that make in-region capacity faster and cheaper than greenfield ownership.

1. CDMO multi-site GMP networks:
   • Networks of qualified GMP sites across regions let a sponsor manufacture in-region without owning a plant, satisfying local-content and supply-security rules.
   • Thermo Fisher’s Patheon network and Catalent’s global sites convert the 500-billion-US-dollar US investment wave into immediately bookable capacity.
2. Modular biomanufacturing:
   • Pre-fabricated biologics modules ship as skid-mounted units and commission in months rather than years, the model WuXi Biologics is deploying in Singapore.
   • Modular lines pair naturally with single-use bioreactors, shortening both build and changeover for multi-product access supply.
3. Technology-transfer toolkits:
   • Standardised process, analytical and comparability packages move a product between sites with minimal revalidation, the engineering step that makes local manufacturing viable.
   • Catalent’s Qai quality-assurance platform exemplifies the digital tooling now wrapping technology transfer to shorten the path from transfer to approved supply.